Publications by authors named "D Meruelo"
This review article provides a comprehensive overview of a novel Sindbis virus vaccine platform as potential immunotherapy for ovarian cancer patients. Ovarian cancer is the most lethal of all gynecological malignancies. The majority of high-grade serous ovarian cancer (HGSOC) patients are diagnosed with advanced disease.
View Article and Find Full Text PDFSindbis alphavirus vectors offer a promising platform for cancer therapy, serving as valuable models for alphavirus-based treatment. This review emphasizes key studies that support the targeted delivery of Sindbis vectors to tumor cells, highlighting their effectiveness in expressing tumor-associated antigens and immunomodulating proteins. Among the various alphavirus vectors developed for cancer therapy, Sindbis-vector-based imaging studies have been particularly extensive.
View Article and Find Full Text PDFOur laboratory has been developing a Sindbis viral (SV) vector platform for treatments of ovarian and other types of cancers. In this study we show that SV.IL-12 combined with an agonistic OX40 antibody can eliminate ovarian cancer in a Mouse Ovarian Surface Epithelial Cell Line (MOSEC) model and further prevent tumors in mice rechallenged with tumor cells after approximately 5 months.
View Article and Find Full Text PDFArticle Synopsis
- The COVID-19 pandemic, caused by SARS-CoV-2, has prompted a global effort to create effective vaccines, with a need for alternatives that provide long-term protection and are cost-effective to manufacture.
- Researchers have developed a new vaccine using a Sindbis alphavirus vector expressing the SARS-CoV-2 spike protein combined with an OX40 immunostimulatory antibody, which has shown promising results in eliciting strong immune responses in mice.
- This novel vaccine approach not only produced lasting neutralizing antibodies and a vigorous T-cell response but also provided effective protection against the coronavirus in mice, highlighting its potential as a candidate for tackling SARS-CoV-2 and other pathogens.
Article Synopsis
- The COVID-19 pandemic, caused by SARS-CoV-2, has led to a global push for effective vaccine development, highlighting the need for new alternatives that ensure long-term protection and can be produced affordably at scale.
- Researchers have developed a novel vaccine using a Sindbis alphavirus vector that expresses the SARS-CoV-2 spike protein combined with an immunostimulatory antibody, showing strong immune responses in mice, including the production of neutralizing antibodies and T-cell activation.
- The study suggests this vaccine platform not only offers significant protection against SARS-CoV-2 but also shows promise for broader applications against other pathogens and variants.